[go: up one dir, main page]

AR023911A1 - Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma - Google Patents

Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma

Info

Publication number
AR023911A1
AR023911A1 ARP990105443A ARP990105443A AR023911A1 AR 023911 A1 AR023911 A1 AR 023911A1 AR P990105443 A ARP990105443 A AR P990105443A AR P990105443 A ARP990105443 A AR P990105443A AR 023911 A1 AR023911 A1 AR 023911A1
Authority
AR
Argentina
Prior art keywords
effector
bronchodilator
pharmaceutical composition
prepare
sulfated polysaccharide
Prior art date
Application number
ARP990105443A
Other languages
English (en)
Original Assignee
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26803748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR023911(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ivax Research Inc filed Critical Ivax Research Inc
Publication of AR023911A1 publication Critical patent/AR023911A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Una composicion farmacéutica para tratar el asma y patologías relacionadas en un mamífero, que comprende cantidades terapéuticamente efectivas de unbroncodilatador y un efector, en donde dicho efector es un polisacárido sulfatado que comprende de 1 aalrededor de 10 residuos de azucar. La composicion puedecomprender además un portador farmacéuticamente aceptable. Preferentemente, el broncodilatador es un agonista adrenérgico beta2 seleccionado del grupointegrado por salmeterol, formoterol, bambuterol, albuterol, terbutalina, pirbuterol, bitolterol, metaproterenol, isoetarina e isoproterenol. En formapreferida, el efector es un polisacárido N-sulfatado, como por ejemplo la heparina que puede ser una heparina de peso molecular ultra bajo (ULMWH) o unaheparina de bajo peso molecular (LMWH). Uso de un broncodilatador y un efector para preparar una composicion farmacéutica de utilidad en un método paraprevenir la tolerancia al broncodilatador en un mamífero que lo necesite, y que comprendela administracion de cantidades terapéuticamente efectivas delbroncodilatador y del efector, en donde dicho efector es un polisacárido sulfatado que comprende de 1 a alrededor de 10 residuos de azucar. De esta manera sepuede prevenir la tolerancia alos mencionados agonistas adrenérgicos beta2, empleados como broncodilatadores.
ARP990105443A 1998-10-30 1999-10-28 Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma AR023911A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10650798P 1998-10-30 1998-10-30
US09/362,540 US6235725B1 (en) 1998-10-30 1999-07-28 Methods and compositions for the prevention of tolerance to medications

Publications (1)

Publication Number Publication Date
AR023911A1 true AR023911A1 (es) 2002-09-04

Family

ID=26803748

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990105443A AR023911A1 (es) 1998-10-30 1999-10-28 Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma
ARP110103258A AR082913A2 (es) 1998-10-30 2011-09-07 Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110103258A AR082913A2 (es) 1998-10-30 2011-09-07 Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma

Country Status (25)

Country Link
US (1) US6235725B1 (es)
EP (1) EP1124563B1 (es)
JP (1) JP4585121B2 (es)
CN (2) CN1329496A (es)
AR (2) AR023911A1 (es)
AT (1) ATE277621T1 (es)
AU (1) AU760119B2 (es)
BR (1) BR9915818A (es)
CA (1) CA2348926C (es)
CO (1) CO5160320A1 (es)
CY (1) CY1107493T1 (es)
CZ (1) CZ297914B6 (es)
DE (1) DE69920734T2 (es)
ES (1) ES2228173T3 (es)
HK (1) HK1041596A1 (es)
HU (1) HUP0302492A3 (es)
IL (2) IL142865A0 (es)
IS (1) IS2321B (es)
NO (1) NO333194B1 (es)
NZ (1) NZ511399A (es)
PL (1) PL195592B1 (es)
PT (1) PT1124563E (es)
SK (1) SK285150B6 (es)
TW (1) TW565451B (es)
WO (1) WO2000025723A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DZ3477A1 (es) * 2000-10-12 2002-04-18
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
WO2003068254A1 (en) * 2002-02-18 2003-08-21 University Of Southampton Glycosaminoglycan-dnase combination therapy
AU2003205898A1 (en) * 2002-02-18 2003-09-04 University Of Southampton Combination therapy for respiratory disorders
DK1511466T4 (en) * 2002-02-18 2015-03-30 Ockham Biotech Ltd Use of glycosaminoglycans, such as, for example, heparin, for the treatment of respiratory disorders such as COPD
PT1494732E (pt) 2002-03-20 2008-03-20 Mannkind Corp Aparelho de inalação
AU2003225182B2 (en) * 2002-04-25 2009-02-26 Momenta Pharmaceuticals, Inc. Methods and products for mucosal delivery
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
CA2496699C (en) * 2002-08-29 2012-07-17 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
US7763280B2 (en) * 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
EP1625851A4 (en) 2003-05-16 2007-12-26 Bbk Bio Corp PREPARATION FOR PREVENTING CONTACT OF PATHOGEN BROOMS WITH A LIVING ORGANISM
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
MX2007001903A (es) 2004-08-20 2007-08-02 Mannkind Corp Catalisis de sintesis de dicetopiperazina.
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
BRPI0707991B8 (pt) 2006-02-22 2021-05-25 Mannkind Corp métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
RU2608439C2 (ru) 2008-06-13 2017-01-18 Маннкайнд Корпорейшн Ингалятор для сухого порошка и система для доставки лекарственных средств
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
CN102647979B (zh) 2009-06-12 2015-03-04 曼金德公司 具有确定比表面积的二酮哌嗪颗粒
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
US20130090371A1 (en) * 2010-04-20 2013-04-11 President And Fellows Of Harvard College Methods and compositions for inhibition of beta2-adrenergic receptor degradation
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
CA2918369C (en) 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
CN104069497A (zh) * 2014-06-27 2014-10-01 东莞市凯法生物医药有限公司 一种降低药物耐受性的组合物、方法及其应用
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20190070244A1 (en) * 2017-06-30 2019-03-07 The New Zealand Institute For Plant And Food Research Limited Boysenberry compositions and methods of preparation and use thereof
MY205941A (en) 2017-08-08 2024-11-21 Odette M Shaw Boysenberry, apple, and blackcurrant compositions and methods of preparation and use therefor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
ATE128350T1 (de) 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
DK0613371T3 (da) * 1991-12-18 2002-05-13 Astrazeneca Ab Ny kombination af formoterol og budesonid
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Also Published As

Publication number Publication date
AU760119B2 (en) 2003-05-08
IS2321B (is) 2007-12-15
EP1124563A2 (en) 2001-08-22
CZ20011518A3 (cs) 2002-04-17
TW565451B (en) 2003-12-11
NO333194B1 (no) 2013-04-02
IS5928A (is) 2001-04-27
CN1329496A (zh) 2002-01-02
ES2228173T3 (es) 2005-04-01
DE69920734D1 (de) 2004-11-04
PL364727A1 (en) 2004-12-13
AU1205100A (en) 2000-05-22
SK285150B6 (sk) 2006-07-07
CA2348926C (en) 2011-08-23
AR082913A2 (es) 2013-01-16
CN100352448C (zh) 2007-12-05
ATE277621T1 (de) 2004-10-15
NZ511399A (en) 2004-09-24
BR9915818A (pt) 2002-06-18
SK5902001A3 (en) 2002-07-02
CO5160320A1 (es) 2002-05-30
NO20012097D0 (no) 2001-04-27
JP2002535245A (ja) 2002-10-22
JP4585121B2 (ja) 2010-11-24
HK1041596A1 (zh) 2002-07-12
WO2000025723A2 (en) 2000-05-11
NO20012097L (no) 2001-06-15
EP1124563B1 (en) 2004-09-29
HUP0302492A2 (hu) 2003-11-28
US6235725B1 (en) 2001-05-22
CY1107493T1 (el) 2013-03-13
CA2348926A1 (en) 2000-05-11
WO2000025723A3 (en) 2000-07-27
HUP0302492A3 (en) 2005-05-30
IL142865A0 (en) 2002-03-10
PL195592B1 (pl) 2007-10-31
CN1572303A (zh) 2005-02-02
DE69920734T2 (de) 2005-10-06
IL142865A (en) 2006-07-05
CZ297914B6 (cs) 2007-04-25
PT1124563E (pt) 2005-01-31
EP1124563A4 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
AR023911A1 (es) Composicion farmaceutica para tratar el asma y patologias relacionadas en un mamifero y uso de un broncodilatador y un efector para preparar la misma
Stern et al. Distal interphalangeal joint arthrodesis: an analysis of complications
AR010385A1 (es) Compuesto derivado de propiofenona, proceso para su preparacion, composicion farmaceutica que lo contiene y uso de dicho compuesto.
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
ES2235311T8 (es) Formulación de budesónida/formoterol para inhalación que tiene una densidad aparente de vertido de 0,30 a 0,36 g/ml, un proceso para preparar la formulación y el uso de la misma.
BR9913152A (pt) Terapias para tratamento de doenças pulmonares
PT915910E (pt) Analogos de exendina, processos para a sua preparacao e medicamentos que os contem
BR9714059A (pt) S-omeprazol em uma forma neutra, processo para preparar o mesmo, uso deste, composição farmacêutica, e, processo para tratar uma condição relacionada com ácido gástrico.
EA200200806A1 (ru) Предупреждение потери и восстановление костной массы некоторыми агонистами простагландина
PT98105A (pt) Processo para a preparacao de formulacoes em aerossol contendo como propulsor 1,1,1,2-tetrafluoroetano
RU93004547A (ru) Фармацевтический состав на основе tanacetum partheniom, способ его получения и лекарственное средство на его основе
BR0012819A (pt) Resina natural, composição de resina, composição de adesivo, produto e processo de preparar uma resina natural
BR9911073A (pt) Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma
AR019681A1 (es) Una formulacion conservante de amplio espectro, un metodo para preparar la formulacion conservante, una solucion de yodo propinilo estabilizadora y un procedimiento para destruir o retardar el crecimiento de procedimiento para destruir o retardar el crecimiento de microbios
ES2178154T3 (es) Proceso de preparacion de formas solidas de dosificacion farmaceutica.
ES2078339T3 (es) Composiciones a base de proantocianidoles; su aplicacion farmacologica.
MXPA97007996A (es) Preparado para el transporte de sustancias activas a traves de barreras.
ES2113727T3 (es) Extraccion con fluidos supercriticos que implican hidrofluoroalcanos.
DK0432036T3 (da) Tørring af korn og frø
Fiaud Theory and practice of vapour phase inhibitors
ES2144404T3 (es) Union de piezas huecas, asi como procedimiento para su fabricacion.
CO5170467A1 (es) Capsulas de eter de celulosa libres de turbiedad y proceso para hacer las mismas
Büchler et al. Arthrodesis of the proximal interphalangeal joint by solid bone grafting and plate fixation in extensive injuries to the dorsal aspect of the finger
BR0006082C1 (pt) Resina epóxi, polifenol glicidilado de um fenol e glioxal,e composição
Rukunga et al. Evaluation of the HIV-1 reverse transcriptase inhibitory properties of extracts from some medicinal plants in Kenya

Legal Events

Date Code Title Description
FC Refusal